Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ripasudil - D Western Therapeutics Institute/Kowa Pharmaceutical

Drug Profile

Ripasudil - D Western Therapeutics Institute/Kowa Pharmaceutical

Alternative Names: Glanatec; K-115; K-115-R; K-321; Ripasudil hydrocholoride hydrate

Latest Information Update: 01 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator D. Western Therapeutics Institute
  • Developer Kowa Pharmaceutical
  • Class Antiglaucomas; Azepines; Eye disorder therapies; Fluorine compounds; Isoquinolines; Small molecules; Sulfonamides
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma; Ocular hypertension
  • Phase III Corneal disorders; Fuchs' endothelial dystrophy
  • Phase II Diabetic retinopathy

Most Recent Events

  • 27 Apr 2023 Kowa Research Institute plans a phase III trial in Fuchs' endothelial dystrophy (Ophthalmic) in April 2023 (NCT05826353)
  • 21 Mar 2023 Phase-III clinical trials in Fuchs' endothelial dystrophy (In the elderly, In adults) in Spain (Ophthalmic)(EudraCT2021-006456-14)
  • 21 Mar 2023 Phase-III clinical trials in Fuchs' endothelial dystrophy (In adults, In the elderly) in Denmark (Ophthalmic) (EudraCT2021-006456-14)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top